Argenx Se (ARGX) Revenue Growth (1y) (2017 - 2026)
Argenx Se (ARGX) Revenue Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | 64.03% |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.40 Bn | 34.39 Bn | 959.66 Mn | 96.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.03% |
| Mar 31, 2026 | 64.30% |
| Dec 31, 2025 | 74.46% |
| Sep 30, 2025 | 96.68% |
| Jun 30, 2025 | 98.60% |
| Mar 31, 2025 | 98.35% |
| Dec 31, 2024 | 96.87% |
| Sep 30, 2024 | 74.11% |
| Jun 30, 2024 | 77.35% |
| Mar 31, 2024 | 82.68% |
| Dec 31, 2023 | 115.89% |
| Sep 30, 2023 | 150.59% |
| Jun 30, 2023 | 259.89% |
| Mar 31, 2023 | 930.20% |
| Dec 31, 2022 | 566.34% |
| Sep 30, 2022 | -99.98% |
| Jun 30, 2022 | -76.25% |
| Mar 31, 2022 | -86.07% |
| Dec 31, 2021 | -6.56% |
| Sep 30, 2021 | 9,813,632.52% |